Framework for assessing causality in disease management programs: Principles

Disease Management

Volumn 6, Issue 3, 2003, Pages 143-158

  Wilson, Thomas ^a   Macdowell, Martin ^b  

^a Informagenics LLC   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; DISEASE MANAGEMENT; EPIDEMIOLOGY; HEALTH CARE COST; METHODOLOGY; OUTCOMES RESEARCH; PATIENT SELECTION; POPULATION; STANDARD;

EID: 0141928906     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/109350703322425491     Document Type: Article

References (37)

1. MacDowell M, Wilson T. Framework for assessing causality in disease management programs. Presented at the Disease Management Association of America Annual Meeting, San Antonio, TX, October 24, 2002. DMAA White Paper available at http://www.dmaa.org/members.html
2. Wilson TW. Epidemiology of value: how to balance clinical and economic value in population health improvement programs. Loveland, OH: Wilson Research, L.L.C., 2001.
3. Krumholz HM, Amatruda J, Smith GL, et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 2002;29:83-89.
4. Riegel B, Carlson B, Kopp Z, LePetri B, Glaser D, Unger A. Effect of a standardized nurse case-management telephone intervention on resource use in patients with chronic heart failure. Arch Intern Med 2002;162:705-712.
5. Ofman JJ, Ryu S, Borenstein J, et al. Identifying patients with gastroesophageal reflux disease in a managed care organization. Am J Health Syst Pharm 2001;58:1607-1613.
6. Disease Management Association of America. Available at: http://www.dmaa.org/definition.html. Accessed September 20, 2002.
7. Nelson EC, Splaine ME, Batalden PB, Plume SK. Building measurement and data collection into medical practice. Ann Intern Med 1998;128:460-466.
8. Berkman LF, Kawachi I, eds. Social epidemiology. New York: Oxford University Press, 2000.
9. Ash AS, Zhao Y, Ellis RP, Kramer MS. Finding future high-cost cases: comparing prior cost versus diagnosis-based methods. HSR Health Serv Res 2001;36:194-206.
10. Cumming RB, Knutson D, Cameron BA, Derrick B. A comparative analysis of claims-based methods of health risk assessments for commercial populations. Society of Actuaries, 2002. Available at: www.soa.org.
11. Brody KK, Johnson RE, Ried DL, Carder PC, Perrin N. A comparison of two methods for identifying frail Medicare-aged persons. J Am Geriatr Soc 2002;50:562-569.
12. Pacala JT, Boult C, Reed RL, Aliberti E. Predictive validity of the Pra instrument among older recipients of managed care. J Am Geriatr Soc 1997;45:614-617.
13. Wilson TW. How I learned to stop worrying and love regression-to-the-mean: case studies from population-based disease management programs. Presented at the American Association of Heath Plans, Building Bridges Conference VIII, Long Beach, CA, April 10, 2002.
14. Agency for Health Care Research and Quality. Clinical classification software (CCS). 2002 software and users guide. Rockville, MD: Agency for Health Care Research and Quality, 2002.
15. Porter R. The greatest benefit to mankind: a medical history of humanity. New York: W.W. Norton & Co., 1997.
16. Schneider EC, Riehl V, Courte-Wienecke S, Eddy DM, Sennett C. Enhancing performance measurement: NCQA's road map for a health information framework. National Committee for Quality Assurance. JAMA 1999;282:1184-1190.
17. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program Arch Intern Med 2001;161:2223-2228.
18. WHO/UNICEF. Primary care. Geneva: World Health Organization, 1978.
19. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-413.
20. Heudebert GR, Centor RM, Klapow JC, Marks R, Johnson L, Wilcox CM. What is heartburn worth? A cost-utility analysis of management strategies. J Gen Intern Med 2000;15:175-182.
21. Kominski GF, Simon PA, Ho A, Luck J, Lim YW, Fielding JE. Assessing the burden of disease and injury in Los Angeles County using disability-adjusted life years. Public Health Rep 2002;117:185-191.
22. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
23. Drummond MF, O'Brien M, Stoddard GL, Torrance GW. Methods for the economic evaluation of health care programs, 2nd edit. Oxford: Oxford University Press, 1997.
24. Engelgau MM, Narayan KM, Herman WH. Screening for type 2 diabetes. Diabetes Care 2000;23:1563-1580.
25. Paltiel AD, Fuhlbrigge AL, Kitch BT, et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the asthma policy model. J Allergy Clin Immunol 2001;108:39-49.
26. Parkin D, Jacoby A, McNamee P, Miller P, Thomas S, Bates D. Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. J Neurol Neurosurg Psychiatry 2000;68:144-149.
27. Algozzine T, Pannone R, Kozma CM. Opinions of disease management programs among medical directors of managed care organizations. Am J Health Syst Pharm 1988;55:1029-1033.
28. American Diabetes Association. Clinical practice recommendations 2002. Diabetes Care 2002;25(Suppl 3).
29. National Asthma Education and Prevention Program. Expert Panel Report 2: guidelines for the diagnosis and management of asthma. NIH Publication 97-4051. Bethesda, MD: National Institutes of Health, 1997.
30. Leape LL, Kabcenell AI, Gandhi TK, Carver P, Nolan TW, Berwick DM. Reducing adverse drug events: lessons from a breakthrough series collaborative. Jt Comm J Qual Improv 2000;26:321-331.
31. Kleinbaum DG, Kupper LL, Muller KE. Applied regression analysis and other multivariable models, 2nd edit. Boston: PWS-Kent, 1988.
32. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-639.
33. Devereaux PJ, Manns BJ, Ghali WA, Quan H, Guyatt GH. The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials 2002;23:380-388.
34. D'Agostino RB. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-2281.
35. Jekal JF, Katz DL, Elmore JG. Epidemiology, biostatistics, and preventive medicine, 2nd edit. Philadelphia: Harcourt Health Services, 2001.
36. Sackett DL. Rules of evidence and clinical recommendations on use of antithrombotic agents. Chest 1986;89(Suppl 2):2S-3S.
37. Bradford-Hill A. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.